| Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. | |
| | |
MedLine Citation:
|
PMID: 21249699 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Gonadotropin-releasing hormone (GnRH) antagonist protocols for pituitary down regulation in in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) allow the use of GnRH agonists for triggering final oocyte maturation. Currently, human chorionic gonadotropin (HCG) is still the standard medication for this purpose. The effectiveness of triggering with a GnRH agonist compared to HCG measured as pregnancy and ovarian hyperstimulation(OHSS) rates are unknown. OBJECTIVES: To compare the effectiveness of a GnRH agonist with HCG for triggering final oocyte maturation in IVF and ICSI patients undergoing controlled ovarian hyperstimulation in a GnRH antagonist protocol followed by embryo transfer. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE , EMBASE, the National Research Register, the Medical Research Council's Clinical Trials Register, and the NHS Centre for Reviews and Dissemination database. We also examined the reference lists of all known primary studies and review articles, citation lists of relevant publications and abstracts of major scientific meetings. SELECTION CRITERIA: All randomised controlled studies (RCTs) reporting data comparing clinical outcomes for women undergoing IVF and ICSI cycles and using a GnRH agonist in comparison with HCG for final oocyte maturation triggering. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. MAIN RESULTS: We identified 11 RCTs (n = 1055). Eight studies assessed fresh autologous cycles and three studies assessed donor-recipient cycles. In fresh-autologous cycles, GnRH agonist was less effective than HCG in terms of the live birth rate per randomised woman (OR 0.44, 95% CI 0.29 to 0.68; 4 RCTs) and ongoing pregnancy rate per randomised woman (OR 0.45, 95% CI 0.31 to 0.65; 8 RCTs). For a group with a 30% live birth or ongoing pregnancy rate using HCG, the rate would be between 12% and 22% using an GnRH agonist. Moderate to severe ovarian hyperstimulation syndrome (OHSS) incidence per randomised woman was significantly lower in the GnRH agonist group compared to the HCG group (OR 0.10, 95% CI 0.01 to 0.82; 5 RCTs). For a group with a 3% OHSS rate using HCG the rate would be between 0% and 2.6% using GnRH agonist. In donor recipient cycles, there was no evidence of a statistical difference in the live birth rate per randomised woman (OR 0.92, 95% CI 0.53 to 1.61; 1 RCT). AUTHORS' CONCLUSIONS: We do not recommend that GnRH agonists be routinely used as a final oocyte maturation trigger in fresh autologous cycles because of lowered live birth rates and ongoing pregnancy rates. An exception could be made for women with high risk of OHSS, after appropriate counselling. |
| | |
Authors:
|
Mohamed Afm Youssef; Fulco Van der Veen; Hesham G Al-Inany; Georg Griesinger; Monique H Mochtar; Ismail Aboulfoutouh; Sherif M Khattab; Madelon van Wely |
Related Documents
:
|
9776489 - Artificial insemination in callithrix jacchus using fresh or cryopreserved sperm. 8563779 - Acoustic parameters for the evaluation of voice of future voice professionals. 8582979 - Sperm morphology using strict criteria after percoll density separation: influence on c... 11853299 - The outcome of sperm retrieval and intracytoplasmic sperm injection for obstructive azo... 2387649 - Changes in human sperm chromatin stability during preparation for in-vitro fertilization. 10840109 - No-scalpel vasal sperm aspiration and in vitro fertilization for the treatment of aneja... 19783709 - Control of the estrous cycle to improve fertility for fixed-time artificial inseminatio... 14526299 - A randomized comparison of two regimens of misoprostol for second-trimester pregnancy t... 10428139 - Effect of diethylstilbestrol on reproductive function. |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Review Date: 2011-01-19 |
Journal Detail:
|
Title: Cochrane database of systematic reviews (Online) Volume: - ISSN: 1469-493X ISO Abbreviation: Cochrane Database Syst Rev Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-01-20 Completed Date: 2011-02-28 Revised Date: 2011-03-09 |
Medline Journal Info:
|
Nlm Unique ID: 100909747 Medline TA: Cochrane Database Syst Rev Country: England |
Other Details:
|
Languages: eng Pagination: CD008046 Citation Subset: IM |
Affiliation:
|
Obstetrics & Gynaecology, Faculty of Medicine - Cairo University, Cairo, Egypt, 1105AZ. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Chorionic Gonadotropin
/
therapeutic use* Female Fertilization in Vitro* Gonadotropin-Releasing Hormone / agonists* Humans Oocyte Donation / methods Oocytes / drug effects, growth & development Ovarian Hyperstimulation Syndrome / epidemiology Ovulation Induction / methods* Pregnancy Pregnancy Rate Randomized Controlled Trials as Topic Sperm Injections, Intracytoplasmic* |
| Chemical | |
Reg. No./Substance:
|
0/Chorionic Gonadotropin; 33515-09-2/Gonadotropin-Releasing Hormone |
| Comments/Corrections | |
Update Of:
|
Cochrane Database Syst Rev. 2010;(11):CD008046
[PMID:
21069701
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical interventions for high grade vulval intraepithelial neoplasia.
Next Document: Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origi...